Rxsight Inc (NASDAQ:RXST) — Market Cap & Net Worth
Market Cap & Net Worth: Rxsight Inc (RXST)
Rxsight Inc (NASDAQ:RXST) has a market capitalization of $228.51 Million ($228.51 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15973 globally and #3754 in its home market, demonstrating a 11.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rxsight Inc's stock price $6.01 by its total outstanding shares 41396609 (41.40 Million). See Rxsight Inc capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Rxsight Inc Market Cap History: 2021 to 2026
Rxsight Inc's market capitalization history from 2021 to 2026. Data shows change from $465.71 Million to $248.79 Million (-17.77% CAGR).
Index Memberships
Rxsight Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.01% | #436 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1562 of 3165 |
Weight: Rxsight Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Rxsight Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rxsight Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.21x
Rxsight Inc's market cap is 3.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $465.71 Million | $22.59 Million | -$48.69 Million | 20.61x | N/A |
| 2022 | $524.50 Million | $49.01 Million | -$66.76 Million | 10.70x | N/A |
| 2023 | $1.67 Billion | $89.08 Million | -$48.61 Million | 18.74x | N/A |
| 2024 | $1.42 Billion | $139.93 Million | -$27.45 Million | 10.17x | N/A |
| 2025 | $431.35 Million | $134.48 Million | -$38.94 Million | 3.21x | N/A |
Competitor Companies of RXST by Market Capitalization
Companies near Rxsight Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Rxsight Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #114 globally with a market cap of $183.80 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #189 globally with a market cap of $124.64 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #238 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #114 | Abbott Laboratories | NYSE:ABT | $183.80 Billion | $105.70 |
| #189 | Stryker Corporation | NYSE:SYK | $124.64 Billion | $325.70 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #238 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $85.39 |
Rxsight Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Rxsight Inc's market cap moved from $465.71 Million to $ 248.79 Million, with a yearly change of -17.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $248.79 Million | -42.32% |
| 2025 | $431.35 Million | -69.69% |
| 2024 | $1.42 Billion | -14.73% |
| 2023 | $1.67 Billion | +218.23% |
| 2022 | $524.50 Million | +12.62% |
| 2021 | $465.71 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Rxsight Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $228.51 Million USD |
| MoneyControl | $228.51 Million USD |
| MarketWatch | $228.51 Million USD |
| marketcap.company | $228.51 Million USD |
| Reuters | $228.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adju… Read more